Abstract
To report on the efficacy and safety of anakinra for treatment of acute gouty arthritis in medically complex, critically ill patients. Retrospective chart review of 13 critically ill hospitalized patients treated with anakinra for 20 episodes of acute gouty arthritis between 2009 and 2014 at a single health plan and institution (HealthPartners Medical Group and Regions Hospital) in Saint Paul, Minnesota. Data was obtained on baseline characteristics, medical comorbidities, reason for hospitalization, prior gout treatment, reason for choosing anakinra over standard therapy, anakinra dosing, response to treatment, and adverse outcomes. A total of 10 patients were in the Intensive Care Unit, 1 was in the Burn Unit for extensive 3rd degree burns, 1 was critically ill with a new diagnosis of hemophagocytic lymphohistiocytosis, and 1 was critically ill in isolation with active disseminated multidrug-resistant tuberculosis. Of these patients, 85% had active infections and 92% had renal insufficiency. All patients had a significant response to anakinra treatment: 50% (10/20 episodes) within 24h, an additional 40% (8/20 episodes) by 48h, and the remaining 10% (2/20 episodes) by 72h. Anakinra was well tolerated with only 1 case of leukop...Continue Reading
References
Jan 13, 2006·Nature·Fabio MartinonJürg Tschopp
Mar 14, 2007·Arthritis Research & Therapy·Alexander SoJürg Tschopp
May 5, 2011·Annals of the Rheumatic Diseases·Naomi SchlesingerAlexander So
May 3, 2012·Arthritis Care & Research·H Ralph SchumacherRobert Terkeltaub
May 8, 2013·Arthritis Care & Research·Pradipta GhoshGregory C Gardner
Jan 17, 2014·Arthritis Research & Therapy·Sébastien OttavianiPhilippe Dieudé
Citations
Aug 3, 2016·Zeitschrift für Rheumatologie·U KiltzJ Braun
Apr 8, 2014·Rheumatic Diseases Clinics of North America·Naomi Schlesinger
Nov 9, 2016·Frontiers in Pharmacology·Antonio VitaleLuca Cantarini
Jul 12, 2017·Expert Opinion on Pharmacotherapy·Tristan Pascart, Pascal Richette
Feb 13, 2018·Drugs & Aging·Eliseo PascualMariano Andrés
Mar 11, 2018·Rheumatology and Therapy·Daniela MarottoStefano Del Giacco
Oct 3, 2017·Rheumatology·Kristen Davies, Marwan A S Bukhari
Jan 3, 2019·Rheumatology·Carly A JanssenMart A F J van de Laar
Jul 3, 2019·The Journal of Rheumatology·Robert T Keenan
Nov 18, 2018·The Journal of Rheumatology·Julianna Desmarais, Cong-Qiu Chu
Jan 17, 2019·The Journal of Rheumatology·Jean W Liew, Gregory C Gardner
Sep 1, 2017·Expert Opinion on Drug Safety·Marta Pérez-De-LisManuel Ramos-Casals
Sep 12, 2020·BMJ Open·Mengtao LiXiaofeng Zeng
Aug 27, 2018·Clinical Rheumatology·Marion ThomasSébastien Ottaviani
Dec 17, 2019·Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders·Ena SharmaRobert Terkeltaub
Jun 12, 2020·Clinical Microbiology Reviews·Joshua S DavisMichael Boyle
Mar 17, 2018·Rheumatology·Tristan Pascart, Frédéric Lioté
May 26, 2017·Clinical Rheumatology·Stefano GentileschiLuca Cantarini
Mar 13, 2021·Frontiers in Pharmacology·Hana MalcovaRudolf Horvath
Apr 16, 2021·International Journal of Immunopathology and Pharmacology·Silvia StefaniaFrancesco Paolo Cantatore
May 17, 2021·Joint, Bone, Spine : Revue Du Rhumatisme·Edoardo CipollettaEmilio Filippucci
Jun 8, 2021·International Immunopharmacology·Hu YuePing Sun
Feb 20, 2021·Arthritis & Rheumatology·Kenneth G SaagRobert Terkeltaub